Dimebon attenuates the Aβ-induced mitochondrial permeabilization

Current Alzheimer Research

Volumn 11, Issue 5, 2014, Pages 422-429

  Shevtsova, Elena F ^a   Vinogradova, Daria V ^a   Kireeva, Elena G ^a   Prakash Reddy, V ^b   Aliev, Gjumrakch ^c,d   Bachurin, Sergey O ^a  

^a INSTITUTE OF PHYSIOLOGICALLY ACTIVE COMPOUNDS   (Russian Federation)

^b MISSOURI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (United States)

^c GALLY International Biomedical Research Consulting LLC   (United States)

^d University of Atlanta   (United States)

Author keywords

Alzheimer disease; Brain and liver mitochondria; Calcium retention capacity; Dimebon; Mitochondrial permeability transition (MPT)

Indexed keywords

ADENINE NUCLEOTIDE TRANSLOCASE; AMYLOID BETA PROTEIN; CALCIUM ION; CYCLOSPORIN A; DIMEBON; CALCIUM; CARRIER PROTEIN; CYCLOSPORIN; ENZYME INHIBITOR; INDOLE DERIVATIVE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE;

ANIMAL TISSUE; ARTICLE; BRAIN MITOCHONDRION; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CONFORMATIONAL TRANSITION; LIVER MITOCHONDRION; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL TOXICITY; MITOCHONDRION SWELLING; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; BRAIN; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; LIVER; MALE; METABOLISM; MITOCHONDRION; PERMEABILITY; PROTEIN CONFORMATION; TIME; ULTRASTRUCTURE; WISTAR RAT;

AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; CALCIUM; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; INDOLES; LIVER; MALE; MITOCHONDRIA; MITOCHONDRIAL ADP, ATP TRANSLOCASES; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; PERMEABILITY; PROTEIN CONFORMATION; RATS; RATS, WISTAR; TIME FACTORS;

EID: 84904038512     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011666140505094808     Document Type: Article

References (42)

1. Burns A, Iliffe S. Alzheimer's disease. BMJ 338: 467-71 (2009).
2. Krieger C, Duchen MR. Mitochondria, Ca2+ and neurodegenerative disease. Eur J Pharmacol 447(2-3): 177-88 (2002).
3. Aliev G, Li Y, Palacios HH, Obrenovich ME. Oxidative Stress Induced Mitochondrial DNA Deletion as a Hallmark forthe Drug Development in the Context of the Cerebrovascular Diseases. Recent Pat Cardiovasc Drug Discov 6(3): 222-41 (2011).
4. Shenk JC, Liu J, Fischbach K, Xu K, Puchowicz M, Obrenovich ME, et al. The effect of acetyl-L-carnitine and R-alpha-lipoic acid treatment in ApoE4 mouse as a model of human Alzheimer's disease. J Neurol Sci 283(1-2): 199-206 (2009).
5. Palacios HH, Yendluri BB, Parvathaneni K, Shadlinski VB, Obrenovich ME, Leszek J, et al. Mitochondrion-specific antioxidants as drug treatments for Alzheimer disease. CNS Neurol Disord Drug Targets 10(2): 149-62 (2011).
6. Bachurin SO. Medicinal and chemical approaches to focused search of agents for treatment and therapy of Alzheimer disease. Vopr Med Khim 47(2): 155-97 (2001).
7. Bachurin SO, Shevtzova EP, Lermontova NN, Serkova TP, Ramsay RR. The effect of dithiocarbamates on neurotoxic action of 1-methyl-4-phenyl-1, 2, 3, 6 tetrahydropyridine (MPTP) and on mitochondrial respiration chain. Neurotoxicology 17(3-4): 897-903 (1996).
8. Obrenovich ME, Li Y, Parvathaneni K, Yendluri BB, Palacios HH, Leszek J, et al. Antioxidants in health, disease and aging. CNS Neurol Disord Drug Targets 10(2): 192-207 (2011).
9. Sullivan PG, Rabchevsky AG, Waldmeier PC, Springer JE. Mitochondrial permeability transition in CNS trauma: cause or effect of neuronal cell death? J Neurosci Res 79(1-2): 231-9 (2005).
10. Mazzeo AT, Beat A, Singh A, Bullock MR. The role of mitochondrial transition pore, and its modulation, in traumatic brain injury and delayed neurodegeneration after TBI. Exp Neurol 218(2): 363-70 (2009).
11. Shevtzova EF, Kireeva EG, Bachurin SO. Effect of beta-amyloid peptide fragment 25-35 on nonselective permeability of mitochondria. Bull Exp Biol Med 132(6): 1173-6 (2001).
12. Vande Velde C, Miller TM, Cashman NR, Cleveland DW. Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria. Proc Natl Acad Sci USA 105(10): 4022-7 (2008).
13. Toman J, Fiskum G. Influence of aging on membrane permeability transition in brain mitochondria. J Bioenerg Biomembr 43: 2-10 (2011).
14. Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO. Mitochondria as a Target for Neurotoxins and Neuroprotective Agents. Ann NY Acad Sci 993: 334-44 (2003).
15. Horecky J, Gvozdjakova A, Kucharska J, E. Obrenovich M, H. Palacios H, Li Y, et al. Effects of Coenzyme Q and Creatine Supplementation on Brain Energy Metabolism in Rats Exposed to Chronic Cerebral Hypoperfusion. Curr Alzheimer Res 8(8): 868-75 (2011).
16. Doody RS, Gavrilova SI, Sano M, Rg T. Effect of Dimebon on cognition, activities of daily living, behavior, and global function in patients with mild-to-moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled study. Lancet 372: 207-15 (2008).
17. Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer's Disease Clinical Development Program [Internet]. [cited 2013 Mar 12]. Available from: http://investors. medivation. com/releasedetail. cfm?ReleaseID=448818.
18. Khritankova IV, Kukharskiy MS, Lytkina OA, Bachurin SO, Shorning BY. Dimebon activates autophagosome components in human neuroblastoma SH-SY5Y cells. Dokl Biochem Biophys 446: 251-3 (2012).
19. Steele JW, Ju S, Lachenmayer ML, Liken J, Stock A, Kim SH, et al. Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain. Mol Psychiatry 18(8): 882-8 (2013).
20. Steele JW, Gandy S. Latrepirdine (Dimebon®), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model. Autophagy 9(4): 617-8 (2013).
21. Zhang S, Hedskog L, Petersen CAH, Winblad B, Ankarcrona M. Dimebon (latrepirdine) enhances mitochondrial function and protects neuronal cells from death. J Alzheimer's Dis 21(2): 389-402 (2010).
22. Eckert SH, Eckmann J, Renner K, Eckert GP, Leuner K, Muller WE. Dimebon ameliorates amyloid-β induced impairments of mitochondrial form and function. J Alzheimer's Dis 31(1): 21-32 (2012).
23. Sims NR, Anderson MF. Isolation of mitochondria from rat brain using Percoll density gradient centrifugation. Nat Protoc 3(7): 1228-39 (2008).
24. Sims NR. Rapid isolation of metabolically active mitochondria from rat brain and subregions using percoll density gradient centrifugation. J Neurochem 55(2): 698-707 (1990).
25. Bradford MM. A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding. Anal Biochem 72: 248-54 (1976).
26. Leung AWC, Varanyuwatana P, Halestrap AP. The Mitochondrial Phosphate Carrier Interacts with Cyclophilin D and May Play a Key Role in the Permeability Transition. J Biol Chem 283(39): 26312-23 (2008).
27. Hansson MJ, Morota S, Teilum M, Mattiasson G, Uchino H, Elmer E. Increased Potassium Conductance of Brain Mitochondria Induces Resistance to Permeability Transition by Enhancing Matrix Volume. J Bioligical Chem 285(1): 741-50 (2010).
28. Varanyuwatana P, Halestrap AP. The roles of phosphate and the phosphate carrier in the mitochondrial permeability transition pore. Mitochondrion 12: 120-5 (2012).
29. Picard M, Csukly K, Robillard M-E, Godin R, Ascah A, Bourcier-Lucas C, et al. Resistance to Ca2+-induced opening of the permeability transition pore differs in mitochondria from glycolytic and oxidative muscles. Am J Physiol-Regul Integr Comp Physiol [Internet] 295(2): R659-68 (2008).
30. Giorgetti M, Gibbons J a, Bernales S, Alfaro IE, Drieu La Rochelle C, Cremers T, et al. Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-aspartate receptor antagonism. J Pharmacol Exp Ther [Internet] 333(3): 748-57 (2010).
31. Bachurin SO, Lermontova N, Shevtzova E, Serkova T, Kireeva E. Prevention of β-amyloid-induced neurotoxicity by tacrine and Dimebon. J Neurochem 71(1) 71: 68 (1998).
32. Naga KK, Geddes JW. Dimebon inhibits calcium-induced swelling of rat brain mitochondria but does not alter calcium retention or cytochrome C release. Neuromolecular Med 13(1): 31-6 (2010).
33. Zorov DB, Juhaszova M, Yaniv Y, Nuss HB, Wang S, Sollott SJ. Regulation and pharmacology of the mitochondrial permeability transition pore. Cardiovasc Res 83: 213-25 (2009).
34. Baines CP. The Molecular Composition of the Mitochondrial Permeability Transition Pore. J Mol Cell Cardiol 46(6): 850-7 (2009).
35. Halestrap AP, Brenner C. The Adenine Nucleotide Translocase: A Central Component of the Mitochondrial Permeability Transition Pore and Key Player in Cell Death. Curr Med Chem 10: 1507-25 (2003).
36. Pestana CR, Silva CHTP, Uyemura SA, Santos AC, Curti C. Impact of adenosine nucleotide translocase (ANT) proline isomerization on Ca2+-induced cysteine relative mobility/mitochondrial permeability transition pore. J Bioenerg Biomembr 42(4): 329-35 (2010).
37. Das M, Parker JE, Halestrap AP. Matrix volume measurements challenge the existence of diazoxide/glibencamide-sensitive KATP channels in rat mitochondria. J Physiol 547(Pt 3): 893-902 (2003).
38. Halestrap AP, McStay GP, Clarke SJ. The permeability transition pore complex: another view. Biochimie 84(2-3): 153-66 (2002).
39. Supnet C, Bezprozvanny I. Neuronal Calcium Signaling, Mitochondrial Dysfunction, and Alzheimer's Disease. J Alzheimer's Dis 20: S487-S498 (2010).
40. Mattson MP. Calcium and neurodegeneration. Aging Cell 6(3): 337-50 (2007).
41. Chalmers S, Nicholls DG. The Relationship between Free and Total Calcium Concentrations in the Matrix of Liver and Brain Mitochondria. J Biol Chem 278(21): 19062-70 (2003).
42. Fernández-Morales J-C, Arranz-Tagarro J-A, Calvo-Gallardo E, Maroto M, Padín J-F, García AG, et al. Stabilizers of Neuronal and Mitochondrial Calcium Cycling as a Strategy for Developing a Medicine for Alzheimer's Disease. ACS Chem Neurosci Am Chem Soc 3(11): 873-83 (2012).